Abstract:

Advances in the diagnosis and management of early gastric cancer （EGC） have positioned super minimally invasive surgery （SMIS） as an increasingly preferred therapeutic strategy，owing to its capacity for organ preservation.However，assessing the curability of SMIS in EGC persists as a critical concern for clinicians and researchers.This review aims to explore the SMIS-Cure evaluation system for assessing therapeutic efficacy in EGC，comparing it with the eCure grading system and analyzing its clinical application value.The SMIS-Cure framework stratifies curability into three tiers： Grade A （cure），Grade B（clinical cure），and Grade C（surgical reassessment）.By integrating tumor-specific parameters and preoperative multimodal imaging to stratify lymph node metastasis risk，this system establishes an evidencebased protocol for optimizing SMIS procedural selection.Prospective applications of this framework are anticipated to standardize SMIS practices，foster multidisciplinary collaboration，and ultimately advance EGC treatment paradigms by striking an optimal balance between radical intervention and organ function preservation.

Key words: Early gastric cancer, Super minimally invasive surgery, Curative resection, Cure evaluation system, Organ preservation